Tags

Type your tag names separated by a space and hit enter

[Should all younger patients with breast cancer be offered adjuvant cytotoxic chemotherapy?].
Ugeskr Laeger. 2000 May 29; 162(22):3184-8.UL

Abstract

The aim of the study was to investigate whether young age at diagnosis is a negative prognostic factor in primary breast cancer and how stage of disease at diagnosis and treatment may influence such an association. It was conducted as a retrospective cohort study based on a population-based data-base of breast cancer diagnosis with detailed information on tumour characteristics, treatment regimens, and vital status and included 10,356 patients with primary breast cancer less than 50 years of age at diagnosis. The main outcome measures were relative risk of dying within the first ten years after diagnosis according to age at diagnosis, adjusted for effect of known prognostic factors and expected mortality. Overall, young patients with low risk disease who did not receive adjuvant treatment had a significantly increasing risk of dying with decreasing age at diagnosis (adjusted relative risk: 45-49 years: 1 (reference); 40-44 years: 1.12 (0.89-1.40); 35-39 years: 1.40 (1.10-1.78); < 35 years: 2.18 (1.64-2.89). However, a similar trend was not seen in young patients who received adjuvant cytotoxic therapy. We found the same difference as above when comparing women receiving no treatment with those receiving adjuvant cytotoxic therapy within strata of node negative patients and patients with the same tumour size. In conclusion, the negative prognostic effect of young age is almost exclusively seen in women diagnosed with low risk disease not receiving adjuvant cytotoxic therapy, whereas young women who receive adjuvant cytotoxic therapy have the same prognosis as middle-aged women. These results suggest that young women with breast cancer, on the basis of age alone, should be regarded as high risk patients and be given adjuvant cytotoxic therapy.

Authors+Show Affiliations

Kroman NT
Afdelingen for epidemiologisk forskning, Statens Serum Institut, København.
Jensen MB
No affiliation info available
Wohlfahrt J
No affiliation info available
Mouridsen H
No affiliation info available
Andersen PK
No affiliation info available
Melbye M
No affiliation info available

MeSH

AdultAge FactorsAgedAntineoplastic AgentsBreast NeoplasmsChemotherapy, AdjuvantDenmarkFemaleHumansMiddle AgedPrognosisProspective StudiesRisk Factors

Pub Type(s)

Comparative Study
English Abstract
Journal Article

Language

dan

PubMed ID

10850209

Citation

Kroman, N T., et al. "[Should All Younger Patients With Breast Cancer Be Offered Adjuvant Cytotoxic Chemotherapy?]." Ugeskrift for Laeger, vol. 162, no. 22, 2000, pp. 3184-8.
Kroman NT, Jensen MB, Wohlfahrt J, et al. [Should all younger patients with breast cancer be offered adjuvant cytotoxic chemotherapy?]. Ugeskr Laeger. 2000;162(22):3184-8.
Kroman, N. T., Jensen, M. B., Wohlfahrt, J., Mouridsen, H., Andersen, P. K., & Melbye, M. (2000). [Should all younger patients with breast cancer be offered adjuvant cytotoxic chemotherapy?]. Ugeskrift for Laeger, 162(22), 3184-8.
Kroman NT, et al. [Should All Younger Patients With Breast Cancer Be Offered Adjuvant Cytotoxic Chemotherapy?]. Ugeskr Laeger. 2000 May 29;162(22):3184-8. PubMed PMID: 10850209.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Should all younger patients with breast cancer be offered adjuvant cytotoxic chemotherapy?]. AU - Kroman,N T, AU - Jensen,M B, AU - Wohlfahrt,J, AU - Mouridsen,H, AU - Andersen,P K, AU - Melbye,M, PY - 2000/6/13/pubmed PY - 2000/7/6/medline PY - 2000/6/13/entrez SP - 3184 EP - 8 JF - Ugeskrift for laeger JO - Ugeskr Laeger VL - 162 IS - 22 N2 - The aim of the study was to investigate whether young age at diagnosis is a negative prognostic factor in primary breast cancer and how stage of disease at diagnosis and treatment may influence such an association. It was conducted as a retrospective cohort study based on a population-based data-base of breast cancer diagnosis with detailed information on tumour characteristics, treatment regimens, and vital status and included 10,356 patients with primary breast cancer less than 50 years of age at diagnosis. The main outcome measures were relative risk of dying within the first ten years after diagnosis according to age at diagnosis, adjusted for effect of known prognostic factors and expected mortality. Overall, young patients with low risk disease who did not receive adjuvant treatment had a significantly increasing risk of dying with decreasing age at diagnosis (adjusted relative risk: 45-49 years: 1 (reference); 40-44 years: 1.12 (0.89-1.40); 35-39 years: 1.40 (1.10-1.78); < 35 years: 2.18 (1.64-2.89). However, a similar trend was not seen in young patients who received adjuvant cytotoxic therapy. We found the same difference as above when comparing women receiving no treatment with those receiving adjuvant cytotoxic therapy within strata of node negative patients and patients with the same tumour size. In conclusion, the negative prognostic effect of young age is almost exclusively seen in women diagnosed with low risk disease not receiving adjuvant cytotoxic therapy, whereas young women who receive adjuvant cytotoxic therapy have the same prognosis as middle-aged women. These results suggest that young women with breast cancer, on the basis of age alone, should be regarded as high risk patients and be given adjuvant cytotoxic therapy. SN - 0041-5782 UR - https://www.unboundmedicine.com/medline/citation/10850209/[Should_all_younger_patients_with_breast_cancer_be_offered_adjuvant_cytotoxic_chemotherapy]_ L2 - http://www.diseaseinfosearch.org/result/960 DB - PRIME DP - Unbound Medicine ER -